# A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors

> **NCT07719920** · PHASE1 · RECRUITING · sponsor: **Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.** · enrollment: 99 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** HW221043 Tablets

## Key facts

- **NCT ID:** NCT07719920
- **Lead sponsor:** Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-10
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2026-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07719920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07719920, "A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07719920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*